Clinical Evidence Requirements
MDR Annex XIV clinical evaluation and post-market clinical follow-up guidance.
Table of Contents
- Clinical Evidence Framework
- Clinical Evaluation Process
- Literature-Based Evidence
- Clinical Investigation Requirements
- Post-Market Clinical Follow-up
Clinical Evidence Framework
Evidence Hierarchy
| Evidence Type | Strength | When to Use |
|---|---|---|
| Randomized Controlled Trial | Highest | Novel Class III, high-risk claims |
| Prospective cohort study | High | New technology, performance claims |
| Retrospective analysis | Medium | Established technology, equivalence |
| Literature review | Medium | Well-characterized, equivalent devices |
| Expert opinion | Low | Supportive only, not primary |
Evidence Requirements by Class
| Class | Minimum Evidence | Clinical Investigation |
|---|---|---|
| I | Risk-benefit analysis | Not typically required |
| IIa | Literature + post-market data | May be required for novel tech |
| IIb | Systematic literature review | Often required for claims |
| III | Comprehensive clinical data | Required unless equivalent |
Clinical Evidence Pathway
Determine evidence strategy:
- Assess device classification and risk level
- Evaluate claim significance (diagnostic, therapeutic)
- Determine if equivalence can be demonstrated
- Identify available literature and clinical data
- Assess gaps requiring additional investigation
- Develop PMCF plan for ongoing evidence
- Validation: Evidence strategy approved by Notified Body
Clinical Evaluation Process
Clinical Evaluation Workflow
Execute clinical evaluation per Annex XIV Part A:
- Identify relevant safety and performance data
- Define scope and search strategy
- Conduct systematic literature search
- Appraise and analyze clinical data
- Assess benefit-risk profile
- Document conclusions in Clinical Evaluation Report (CER)
- Plan post-market clinical follow-up
- Validation: CER reviewed by qualified clinical evaluator
Clinical Evaluation Report Structure
CLINICAL EVALUATION REPORT (CER)
├── 1. Executive Summary
│ ├── Device description and intended purpose
│ ├── Conclusions on safety and performance
│ └── Benefit-risk conclusion
├── 2. Scope of Clinical Evaluation
│ ├── Device identification
│ ├── Clinical claims to be evaluated
│ └── Equivalence assessment (if applicable)
├── 3. Clinical Background
│ ├── Disease/condition overview
│ ├── Current treatment options
│ └── State of the art
├── 4. Clinical Data Sources
│ ├── Pre-clinical data (bench, animal)
│ ├── Clinical investigation data
│ ├── Literature search methodology
│ └── Post-market surveillance data
├── 5. Data Appraisal
│ ├── Study quality assessment
│ ├── Relevance to subject device
│ └── Data contribution to evaluation
├── 6. Data Analysis
│ ├── Safety analysis
│ ├── Performance analysis
│ └── Benefit-risk determination
├── 7. Conclusions
│ ├── Clinical evidence summary
│ ├── Residual risks
│ └── PMCF requirements
└── 8. PMCF Plan Summary
├── Data gaps identified
├── PMCF activities planned
└── Update schedule
Qualified Clinical Evaluator
Requirements per Annex XIV:
- Medical degree or equivalent healthcare qualification
- 4+ years clinical experience in relevant field OR
- Research background in relevant domain
- Training in clinical evaluation methodology
- Understanding of MDR requirements
Literature-Based Evidence
Literature Search Strategy
Execute systematic literature review:
- Define PICO question (Population, Intervention, Comparison, Outcome)
- Develop search string with Boolean operators
- Select databases (PubMed, Embase, Cochrane, etc.)
- Set date range and language filters
- Execute search and document results
- Screen abstracts and full texts
- Validation: Reproducible search, documented exclusion criteria
Database Selection
| Database | Coverage | Best For |
|---|---|---|
| PubMed/MEDLINE | Biomedical literature | Primary clinical data |
| Embase | Drugs, devices, biomedical | European studies |
| Cochrane Library | Systematic reviews | Meta-analyses |
| CINAHL | Nursing, allied health | User studies |
| IEEE Xplore | Engineering | Technical performance |
| Manufacturer data | Proprietary | Direct device data |
Data Appraisal Criteria
Evaluate each source:
| Criterion | Assessment | Score |
|---|---|---|
| Study design | RCT > cohort > case series | 1-5 |
| Sample size | Statistical power adequate | 1-5 |
| Follow-up duration | Sufficient for outcomes | 1-5 |
| Population relevance | Matches IFU population | 1-5 |
| Device equivalence | Technical, biological, clinical | 1-5 |
| Bias risk | Low/medium/high | 1-5 |
Equivalence Assessment
Demonstrate equivalence per MDCG 2020-5:
Technical equivalence:
- Similar design
- Same materials
- Same specifications
- Same manufacturing process
Biological equivalence:
- Same tissue contact
- Same biocompatibility
- Same sterilization method
Clinical equivalence:
- Same intended purpose
- Same clinical condition
- Same patient population
- Same user (professional/lay)
Clinical Investigation Requirements
When Investigation is Required
Clinical investigation mandatory:
- Class III implantable devices (Article 61(4))
- Novel technology without equivalent
- Significant modification to existing device
- New clinical claims not supported by literature
- Addressing gaps identified in clinical evaluation
Clinical Investigation Workflow
Conduct clinical investigation:
- Develop Clinical Investigation Plan (CIP)
- Submit to Ethics Committee for approval
- Notify Competent Authority (via EUDAMED)
- Conduct investigation per GCP principles
- Collect and analyze clinical data
- Prepare Clinical Investigation Report
- Submit serious adverse event reports (within 7-15 days)
- Validation: All subjects completed, data lock achieved
Clinical Investigation Plan Elements
| Section | Content |
|---|---|
| Objectives | Primary and secondary endpoints |
| Design | Randomized, controlled, blinded |
| Population | Inclusion/exclusion criteria |
| Sample size | Statistical justification |
| Procedures | Visit schedule, assessments |
| Endpoints | Safety and performance measures |
| Analysis | Statistical methods |
| Safety | Adverse event definitions, reporting |
Ethics Committee Submission
Required documentation:
- Clinical Investigation Plan
- Investigator's Brochure
- Informed consent documents
- Case Report Forms
- Investigator CVs
- Insurance certificate
- Device documentation
Post-Market Clinical Follow-up
PMCF Plan Requirements
Develop PMCF Plan per Annex XIV Part B:
- Identify residual risks from clinical evaluation
- Define clinical questions to address
- Select PMCF methods (survey, registry, study)
- Specify endpoints and success criteria
- Define timeline and milestones
- Plan data collection and analysis
- Schedule PMCF Evaluation Report updates
- Validation: PMCF Plan approved by Notified Body
PMCF Methods
| Method | Description | Best For |
|---|---|---|
| Literature review | Ongoing systematic search | Mature devices |
| Survey | User/patient questionnaire | Real-world experience |
| Registry | Multi-site data collection | Long-term outcomes |
| PMCF study | Prospective clinical study | Specific questions |
| Complaint analysis | Structured complaint review | Safety signals |
| Vigilance data | MAUDE, EUDAMED analysis | Comparative safety |
PMCF Evaluation Report
Update frequency:
| Device Class | Update Frequency |
|---|---|
| Class III | Annual |
| Class IIb implantable | Annual |
| Class IIb | Every 2 years |
| Class IIa | Every 2-5 years |
| Class I | When clinically relevant |
PMCF Report Structure
PMCF EVALUATION REPORT
├── 1. Executive Summary
│ └── Key findings and conclusions
├── 2. Scope
│ ├── Device covered
│ └── Reporting period
├── 3. PMCF Activities
│ ├── Methods employed
│ └── Data sources
├── 4. Results
│ ├── Safety data
│ ├── Performance data
│ └── Clinical questions addressed
├── 5. Conclusions
│ ├── Benefit-risk confirmation
│ ├── Residual risks updated
│ └── Need for corrective action
└── 6. Next Steps
├── CER update requirements
└── PMCF Plan modifications
Integration with CER
PMCF data feeds clinical evaluation:
- PMCF data collected per plan
- Data analyzed in PMCF Evaluation Report
- CER updated with PMCF conclusions
- Risk management file updated
- IFU updated if needed
- Validation: CER update cycle completed